Preoperative iLux on Cataract Surgery Derived Dry Eye Disease Due to Meibomian Gland Dysfunction
Completed · Not applicable
Conditions studied: Dry Eye Disease, Meibomian Gland Dysfunction, Cataract Senile, Dry Eye Syndromes
In brief
This prospective study will investigate the effect of pre-operative Systane iLux system administration in treated cataract induced dry eye disease.
Key facts
- Study ID
- NCT06483750
- Run by
- George Washington University
- People needed
- 30
- Starts
- 2024-06-03
- Expected to finish
- 2025-02-01
- Last updated by the study team
- 2026-05-15
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Age greater than 18 at the time of informed consent
- Must understand; be willing and able, and likely to fully comply with study procedures, visit schedule, and restrictions
- Upcoming scheduled senile cataract surgery
You may not qualify if…
- Eyelid abnormalities
- Patients with active ocular infection, active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months
- Ocular surgery within the last 6 months
- Occlusion therapy with lacrimal or punctum plugs within the last 3 months
- Patients with an ocular surface abnormality that may compromise corneal integrity
- Patients with ocular injury or trauma, chemical burns, or limbal stem cell deficiency (within prior 3 months)
- Patients with cicatricial lid margin disease
- patients with lid surface abnormalities that affect lid function in either eye; patients with aphakia
- Patients with permanent makeup or tattoos on their eyelids.
- Previous application/administration of Systane iLux or LipiFlow treatment
Where it is running
- George Washington University — Washington D.C., District of Columbia, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.